A federal appeals court has revived more than 750 lawsuits filed over four diabetes drugs after finding that a San Diego judge misapplied a 2011 U.S. Supreme Court opinion relating to federal pre-emption.
In a Dec. 6 unpublished memorandum, the U.S. Court of Appeals for the Ninth Circuit punted on a key issue in the case: whether the manufacturers of the drugs, under the Supreme Court’s 2009 holding in Wyeth v. Levine, could provide “clear evidence” that the Food and Drug Administration would “not have approved” changes to the drugs’ labeling that plaintiffs alleged were necessary to warn of links to pancreatic cancer.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]